Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Cash from Operations (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Cash from Operations for 14 consecutive years, with 38448000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 35.98% to 38448000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 141996000.0 through Dec 2025, down 28.39% year-over-year, with the annual reading at 141996000.0 for FY2025, 28.39% down from the prior year.
  • Cash from Operations hit 38448000.0 in Q4 2025 for Corcept Therapeutics, down from 54481000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 73293000.0 in Q3 2024 to a low of 5128000.0 in Q1 2025.
  • Historically, Cash from Operations has averaged 37759350.0 across 5 years, with a median of 39818000.0 in 2024.
  • Biggest five-year swings in Cash from Operations: tumbled 83.44% in 2023 and later surged 986.24% in 2024.
  • Year by year, Cash from Operations stood at 49427000.0 in 2021, then crashed by 32.45% to 33388000.0 in 2022, then crashed by 83.44% to 5529000.0 in 2023, then soared by 986.24% to 60058000.0 in 2024, then plummeted by 35.98% to 38448000.0 in 2025.
  • Business Quant data shows Cash from Operations for CORT at 38448000.0 in Q4 2025, 54481000.0 in Q3 2025, and 43939000.0 in Q2 2025.